RPL14 (Ribosomal Protein L14) is a component of the 60S large ribosomal subunit, playing a crucial role in protein synthesis and cellular homeostasis. Mutations in RPL14 are associated with Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome. Beyond its role in hematologic disease, ribosomal protein dysfunction has emerged as a significant area of investigation in neurodegenerative disease research.
| Attribute | Value |
|---|---|
| Gene Symbol | RPL14 |
| Full Name | Ribosomal Protein L14 |
| Chromosomal Location | 3p21.2 |
| NCBI Gene ID | 6132 |
| Ensembl ID | ENSG00000165006 |
| UniProt ID | P50914 |
RPL14 is a 23 kDa ribosomal protein consisting of 215 amino acids. It is located on the surface of the 60S ribosomal subunit, where it participates in the formation of the ribosomal functional center.
RPL14 participates in several critical cellular processes:
While RPL14 is primarily studied in the context of Diamond-Blackfan anemia, ribosomal dysfunction is increasingly recognized as a contributor to neurodegenerative processes.
Ribosomal proteins like RPL14 play essential roles in maintaining proteostasis—the delicate balance between protein synthesis and degradation. Disruption of this balance is a hallmark of several neurodegenerative diseases:
Alzheimer's Disease (AD): Impairment of ribosomal function contributes to reduced protein synthesis in affected neurons. Studies have shown that ribosomal stress can lead to the accumulation of misfolded proteins, including amyloid-beta and tau, which are characteristic of AD pathology.
Parkinson's Disease (PD): Ribosomal dysfunction may contribute to the degeneration of dopaminergic neurons. The integrated stress response (ISR), which is activated by various cellular stresses including ribosomal stress, has been implicated in PD pathogenesis.
Amyotrophic Lateral Sclerosis (ALS): Mutations in ribosomal proteins and translation factors have been linked to ALS, suggesting a role for ribosomal dysfunction in motor neuron degeneration.
Ribosomal stress can trigger a cascade of events leading to protein aggregation:
RPL14 mutations account for approximately 5% of DBA cases[1]. The disease is characterized by:
DBA is thought to result from haploinsufficiency of ribosomal proteins, leading to ribosomal stress and activation of the p53 pathway[2].
Although direct associations between RPL14 and neurodegenerative diseases remain under investigation, the following connections are proposed:
RPL14 is ubiquitously expressed across all tissues, with high expression in:
In the brain, RPL14 expression is particularly notable in:
The ribosome-nascent chain complex (RNC) plays a critical role in co-translational protein folding and quality control. RPL14, as a component of the 60S subunit, contributes to the proper positioning of the nascent chain within the ribosomal tunnel. Defects in RPL14 can lead to:
The RQC pathway specifically targets stalled ribosomes, leading to the addition of ubiquitin-like modifications to incomplete polypeptides. Failure of RQC has been implicated in protein aggregation diseases including AD, PD, and ALS[4].
Neurons exhibit unique vulnerabilities to ribosomal dysfunction due to their:
RPL14 dysfunction in these contexts can contribute to:
While RPL14 is primarily a cytoplasmic ribosomal protein, ribosomal function is closely linked to mitochondrial protein synthesis. Mitochondria contain their own ribosomes (mitoribosomes) that synthesize critical components of the electron transport chain. Ribosomal dysfunction can impair:
This connection is particularly relevant in PD, where mitochondrial dysfunction is a central pathological feature.
The Integrated Stress Response is a central signaling pathway activated by various forms of cellular stress, including ribosomal stress. When ribosomal function is compromised:
RPL14 deficiency can trigger ISR activation through nucleolar stress mechanisms, leading to downstream effects on neuronal survival[7].
The mTOR (mammalian Target of Rapamycin) pathway is a central regulator of cell growth and protein synthesis. In neurodegenerative diseases:
Modulating mTOR activity with rapamycin or related compounds has shown neuroprotective effects in various models of neurodegeneration.
Ribosomal proteins, including RPL14, play important roles in regulating p53 activity:
In Alzheimer's disease, RPL14 dysfunction contributes to several key pathological features:
Studies of AD brain tissue have consistently shown altered expression of ribosomal proteins, suggesting that ribosomal dysfunction is not merely a consequence but an active contributor to disease pathogenesis[8].
In Parkinson's disease:
RPL14 and other ribosomal proteins are implicated in ALS through:
Overlapping pathology between ALS and FTD includes:
Understanding RPL14 function has informed several therapeutic strategies:
Translation modulators: Drugs that normalize translation rates in neurons
Stress granule modulators: Preventing harmful sequestration of ribosomal proteins
Autophagy enhancers: Promoting clearance of misfolded proteins
Gene therapy approaches: Viral vector delivery of wild-type ribosomal proteins
Current research focuses on:
Kusner JD, Pytel P, Robustelli B, et al. Characterization of ribosomal protein gene mutations in Diamond-Blackfan anemia. Blood. 2004. ↩︎
Narla A, Hurst SN, Ebert BL. Ribosome defects in Diamond-Blackfan anemia. Blood. 2011. ↩︎
Ishimura R, Nagy G, Liao PC, et al. Ribosome stalling and quality control in neurodegeneration. Nat Rev Neurol. 2014. ↩︎
Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2015. ↩︎
Ciechanover A, Kwon YT. Protein homeostasis and neurodegeneration. Exp Neurobiol. 2014. ↩︎
Pearson C, Vincent AE, Gorman GS, et al. Mitochondrial translation in neurodegenerative disease. J Clin Invest. 2018. ↩︎
De Keersmaeker K, Van Roosbroeck K, Van Vlierberghe P. p53 activation in ribosomal stress signaling. Cell Cycle. 2017. ↩︎
Hernandez-Ortega K, Garcia-Esparcia P, Lopez-Gonzalez I, et al. Altered ribosomal protein expression in Alzheimer disease brain. J Neuropathol Exp Neurol. 2016. ↩︎